What Loxo Oncology, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bilenker Joshua H. | President & CEO | Feb 15 | Disposition to Issuer · D | −30,000 | $235.00 | −$7.05M | 0 |
| Bilenker Joshua H. | President & CEO | Feb 15 | Disposition to Issuer · D | −162,707 | $235.00 | −$38.2M | 0 |
| Nanda Nisha | Chief Development Officer | Feb 15 | Disposition to Issuer · D | −18,896 | $235.00 | −$4.44M | 0 |
| Elms Steve | Director | Feb 15 | Tender Offer · U | −2,038,920 | $235.00 | −$479M | 2,038,920 |
| Van Naarden Jacob | Chief Operating Officer | Feb 15 | Disposition to Issuer · D | −19,000 | $235.00 | −$4.47M | 0 |
| Flaherty Keith T. | Director | Feb 15 | Disposition to Issuer · D | −9,732 | $235.00 | −$2.29M | 0 |
| Naider Avi Z. | Director | Feb 15 | Disposition to Issuer · D | −111,843 | $235.00 | −$26.3M | 0 |
| Naider Avi Z. | Director | Jan 31 | Gift · G | −15,000 | — | — | 111,843 |
| Naider Avi Z. | Director | Dec 13 | Open-market buy · P | +725 | $138.92 | +$101K | 126,843 |
| Burstein Jennifer | Senior VP of Finance | Dec 11 | Open-market sale · S | −100 | $140.48 | −$14K | 0 |
| Burstein Jennifer | Senior VP of Finance | Dec 11 | Open-market sale · S | −100 | $139.36 | −$13.9K | 100 |
| Burstein Jennifer | Senior VP of Finance | Dec 11 | Open-market sale · S | −263 | $137.88 | −$36.3K | 200 |
| Burstein Jennifer | Senior VP of Finance | Dec 11 | Open-market sale · S | −587 | $136.98 | −$80.4K | 463 |
| Burstein Jennifer | Senior VP of Finance | Dec 11 | Open-market sale · S | −200 | $135.69 | −$27.1K | 1,050 |
| Burstein Jennifer | Senior VP of Finance | Dec 11 | Exercise / conversion · M | +1,250 | $11.35 | +$14.2K | 1,250 |
| Bilenker Joshua H. | President & CEO | Dec 11 | Open-market sale · S | −100 | $140.61 | −$14.1K | 164,407 |
| Bilenker Joshua H. | President & CEO | Dec 11 | Open-market sale · S | −1,200 | $140.15 | −$168K | 164,507 |
| Bilenker Joshua H. | President & CEO | Dec 11 | Open-market sale · S | −1,100 | $139.05 | −$153K | 165,707 |
| Bilenker Joshua H. | President & CEO | Dec 11 | Open-market sale · S | −2,407 | $137.63 | −$331K | 166,807 |
| Bilenker Joshua H. | President & CEO | Dec 11 | Open-market sale · S | −3,393 | $136.79 | −$464K | 169,214 |
Loading...
